Chaperones and slow death - A recipe for tumor immunotherapy

Trends in Biotechnology

Volumn 23, Issue 2, 2005, Pages 57-59

  Calderwood, Stuart K ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; CELLS; IMMUNOLOGY; POPULATION STATISTICS; REGRESSION ANALYSIS; TUMORS;

IMMUNITY; METASTATIC TUMORS; MOLECULAR CHAPERONE HSP70; TUMOR IMMUNOTHERAPY;

BIOTECHNOLOGY;

CHAPERONE; HEAT SHOCK PROTEIN 70; TUMOR ANTIGEN;

AUTOIMMUNITY; BIOENGINEERING; CANCER IMMUNOTHERAPY; CELL DEATH; CELL POPULATION; CELL PROLIFERATION; ENVIRONMENTAL FACTOR; IMMUNITY; MELANOCYTE; MELANOGENESIS; MELANOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR; TUMOR IMMUNITY; TUMOR REGRESSION;

EID: 12344292277     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2004.12.011     Document Type: Short Survey

References (22)

1. D. Pardoll Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21 2003 807 839
2. S. Chouaib Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death Tissue Antigens 60 2002 273 281
3. P. Moller, and G. Hammerling The role of surface HLA A, B, C molecules in tumor immunity Cancer Surv. 13 1992 101 127
4. M. Larsson Dendritic cells resurrect antigens from dead cells Trends Immunol. 22 2001 141 148
5. G.A. Daniels A simple method to cure established tumors by inflammatory killing of normal cells Nat. Biotechnol. 22 2004 1125 1132
6. V.H. Engelhard Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy Immunol. Rev. 188 2002 136 146
7. P. Srivastava Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses Annu. Rev. Immunol. 20 2002 395 425
8. C. Castelli Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer Cancer Immunol. Immunother. 53 2004 227 233
9. M.H. Manjili Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110 Cancer Res. 62 2002 1737 1742
10. S.M. Todryk Facets of heat shock protein 70 show immunotherapeutic potential Immunology 110 2003 1 9
11. D.G. Millar Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo Nat. Med. 9 2003 1469 1476
12. S. Todryk Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake J. Immunol. 163 1999 1398 1408
13. E. Noessner Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells J. Immunol. 169 2002 5424 5432
14. T. Becker CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes J. Cell Biol. 158 2002 1277 1285
15. A. Asea HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine Nat. Med. 6 2000 435 442
16. A. Asea Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4 J. Biol. Chem. 277 2002 15028 15034
17. P. Srivastava Hypothesis: controlled necrosis as a tool for immunotherapy of human cancer Cancer Immun. 3 2003 4
18. A. Melcher Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression Nat. Med. 4 1998 581 587
19. S. Gallucci Natural adjuvants: endogenous activators of dendritic cells Nat. Med. 5 1999 1249 1255
20. X.F. Huang A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine Cancer Res. 63 2003 7321 7329
21. F. Belli Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings J. Clin. Oncol. 20 2002 4169 4180
22. S. Lindquist, and E.A. Craig The heat shock proteins Annu. Rev. Genet. 22 1988 631 637